Kiniksa Pharmaceuticals Ltd (KNSA)

$17.61 0.00 (0.00%)

16:00 EDT KNSA Stock Quote Delayed 30 Minutes

KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings Apr 23, 2024

KNSA stock results show that Kiniksa Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

The 3 Most Undervalued Biotech Stocks to Buy in December

7 Underappreciated Biotech Stocks to Pick Up on the Cheap

3 Small-Cap Stocks That Are Worth the Gamble

Volume:

Previous Close -

Market Cap 1.24B

PE Ratio 92.68

EPS 0.19

Volume (Avg. Vol.)

Day's Range -

52-Week Range $10.65 - $22.09

Dividend & Yield N/A (N/A)

KNSA Stock Predictions, Articles, and Kiniksa Pharmaceuticals Ltd News

From InvestorPlace
From the Web

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

By Josh Enomoto, InvestorPlace Contributor Apr 5, 2023

Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own.

7 Small-Cap Stocks to Buy for Explosive Growth Potential

By Josh Enomoto, InvestorPlace Contributor Mar 30, 2023

Although small-cap stocks to buy presents higher risks than the large caps, the segment also enjoys critical advantages.

7 Dirt-Cheap Stocks Sitting in the Sweet Spot

By Josh Enomoto, InvestorPlace Contributor Mar 23, 2023

These cheap stocks don’t just attract on the ticker tape but rather feature compelling fundamentals and analysts’ upside projections.

The Top 7 Growth Stocks in Biotech

By Alex Sirois, InvestorPlace Contributor Mar 3, 2023

The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.

(NASDAQ:KNSA)

From Seeking Alpha Feb 28, 2024

Kiniksa Pharmaceuticals beats earnings expectations in Q4 2023, with a GAAP EPS of $0.35 and revenue of $83.4M.

Kiniksa Pharmaceuticals GAAP EPS of -$0.20 misses by $0.03, revenue of $67.05M beats by $2.6M (NASDAQ:KNSA)

From Seeking Alpha Oct 31, 2023

Kiniksa Pharmaceuticals reports Q3 financial results: GAAP EPS misses by $0.03, but revenue beats estimates.

Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday

From The Motley Fool Jul 25, 2023

The company reported a big jump in revenue and updated guidance.

Kiniksa Pharmaceuticals GAAP EPS of $0.21 beats by $0.38, revenue of $71.47M beats by $19.27M (NASDAQ:KNSA)

From Seeking Alpha Jul 25, 2023

Kiniksa Pharmaceuticals press release (KNSA): Q2 GAAP EPS of $0.21 beats by $0.38.Revenue of $71.47M (+165.0% Y/Y) beats by $19.27M.Total revenue for the second quarter of 2023...

Kiniksa stock soars after guidance raise for pericarditis therapy

From Seeking Alpha May 2, 2023

Kiniksa Pharmaceuticals (KNSA) rose ~14% Tuesday on better-than-expected Q1 2023 financials and guidance raise for Arcalyst pericarditis therapy. Read more here.

Kiniksa Pharmaceuticals (KNSA) Receives a Buy from J.P. Morgan

From TipRanks Aug 11, 2022

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report) on August 9 and set a price target of $19.00. The ...

Kiniksa Pharmaceuticals Ltd (KNSA)

KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024

The 3 Most Undervalued Biotech Stocks to Buy in December

7 Underappreciated Biotech Stocks to Pick Up on the Cheap

3 Small-Cap Stocks That Are Worth the Gamble

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Kiniksa Pharmaceuticals Ltd (KNSA)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

KNSA Stock Predictions, Articles, and Kiniksa Pharmaceuticals Ltd News

Subscriber Sign in